<SEC-DOCUMENT>0001213900-21-049470.txt : 20210923
<SEC-HEADER>0001213900-21-049470.hdr.sgml : 20210923
<ACCEPTANCE-DATETIME>20210923090026
ACCESSION NUMBER:		0001213900-21-049470
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210922
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210923
DATE AS OF CHANGE:		20210923

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		211271173

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea147815-8k_actinium.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ATNM="http://actiniumpharma.com/20210922">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_ATNM_actiniumpharma.com_20210922 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20210922_20210922 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0001388320 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-09-22to2021-09-22" name="dei:EntityCentralIndexKey">0001388320</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-09-22to2021-09-22" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="atnm-20210922.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-09-22to2021-09-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-22</xbrli:startDate>
        <xbrli:endDate>2021-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>



<p style="margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_901_edei--DocumentType_c20210922__20210922_zqeTwk2mGQTh"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d) of the</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
<span id="xdx_90D_edei--DocumentPeriodEndDate_c20210922__20210922_zL04m62QljX2"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 22, 2021</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityRegistrantName_c20210922__20210922_zKQBG3M1VDIa"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" name="dei:EntityRegistrantName">ACTINIUM PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 34%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20210922__20210922_z2OdtVI7Fxcf"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityFileNumber_c20210922__20210922_zX6TuvllcuP5"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" name="dei:EntityFileNumber">001-36374</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20210922__20210922_zeC5QKZFEQYb"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" name="dei:EntityTaxIdentificationNumber">74-2963609</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b>(State or other jurisdiction<br />
of incorporation)</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>(Commission File Number)</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>(IRS Employer<br />
Identification No.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<span id="xdx_90D_edei--EntityAddressAddressLine1_c20210922__20210922_zswMWu7LVeBi"><b><span style="text-decoration: underline"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" name="dei:EntityAddressAddressLine1">275
Madison Avenue</ix:nonNumeric></span></b></span><b><span style="text-decoration: underline">, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20210922__20210922_zzifvCbBiOC9"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" name="dei:EntityAddressAddressLine2">7<sup>th</sup>
Floor</ix:nonNumeric></span></span></b><b><span style="text-decoration: underline">, <span id="xdx_90F_edei--EntityAddressCityOrTown_c20210922__20210922_zpOSHtAgxBp2"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20210922__20210922_zd1L3SkFNPX9"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> </span></b><b><span style="text-decoration: underline"><span id="xdx_90E_edei--EntityAddressPostalZipCode_c20210922__20210922_zpJUjJ55BjIe"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" name="dei:EntityAddressPostalZipCode">10016</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address of Principal Executive Offices)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number: <span id="xdx_901_edei--CityAreaCode_c20210922__20210922_zYguQTfrRI16"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" name="dei:CityAreaCode">(646)</ix:nonNumeric></span> <span id="xdx_902_edei--LocalPhoneNumber_c20210922__20210922_zX6WHG8tIduj"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" name="dei:LocalPhoneNumber">677-3870</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former name or former address, if changed since
last report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="text-decoration: underline">see</span>&#160;General
Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt"><span id="xdx_90C_edei--WrittenCommunications_c20210922__20210922_zreOeThOIRrh"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt"><span id="xdx_90F_edei--SolicitingMaterial_c20210922__20210922_zr933E8gB2T8"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt"><span id="xdx_906_edei--PreCommencementTenderOffer_c20210922__20210922_zSalYZmeHAah"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt"><span id="xdx_908_edei--PreCommencementIssuerTenderOffer_c20210922__20210922_z6s63HA97bK1"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 34%; text-align: center"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt"><b><span id="xdx_909_edei--Security12bTitle_c20210922__20210922_zavE28j3HvK3"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b><span id="xdx_906_edei--TradingSymbol_c20210922__20210922_zywfIVVMyoA6"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" name="dei:TradingSymbol">ATNM</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b><span id="xdx_903_edei--SecurityExchangeName_c20210922__20210922_zpfdD51qsqcc"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: right; text-indent: 0.5in">Emerging growth company&#160;<span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20210922__20210922_zNiwF7kKqWv1"><ix:nonNumeric contextRef="From2021-09-22to2021-09-22" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Dr. Mark S. Berger, the
Chief Medical Officer of Actinium Pharmaceuticals, Inc. (the &#8220;Company&#8221;), notified the Company that he will be resigning effective
as of September 24, 2021. Dr.&#160;Berger&#8217;s resignation is not the result of any disagreement with the Company or its Board of Directors
or any matter relating to the Company&#8217;s operations, policies, or practices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 7.01 Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 23, 2021, the Company issued a
press release, which is attached hereto as Exhibit 99.1, announcing multiple senior leadership appointments and promotions including
Arun Swaminathan, Ph.D., as Chief Business and Commercial Officer, Paul Diamond, Ph.D., as Vice President, Patent and Legal Counsel,
and the promotion of Avinash Desai, M.D., to the position of Chief Medical Officer from his previous position of Executive Vice
President, Clinical Development, Operations, and Medical Affairs. The Company undertakes no obligation to update, supplement or
amend the materials attached hereto as Exhibit 99.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Swaminathan is a highly accomplished executive
with over 20 years of experience in the global biopharmaceutical industry, which has included increasing positions of responsibility across
commercial, business development, and clinical roles. He has a proven track record of converting great science into successful business
opportunities. Prior to joining Actinium, Dr. Swaminathan was the Chief Business Officer and Senior Vice President at Alteogen Inc. a
South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics. In this role, his
negotiations with partners led to deals totaling over $6 billion in potential value, including agreements with two of the top ten global
pharmaceutical companies. During his tenure at Alteogen, the Company&#8217;s market value increased from approximately $400 million to
over $4 billion. Dr. Swaminathan joined Alteogen after they entered into an agreement with Lynkogen Inc. and gained full rights to develop
the assets. As CEO and co-founder of Lynkogen, he raised capital, in-licensed potentially transformative drug candidates to address complex
metabolic diseases and advanced Lynkogen from concept to a pre-clinical stage company with a lead drug candidate ready for IND enabling
studies that he successfully negotiated for out-licensing. Previously, Dr. Swaminathan held commercial and business development roles
at Bristol Myers Squibb over 12 years during two tenures, most recently as Worldwide Brand Director, where he managed products with over
$2 billion in annual sales across the top 10 global markets. Earlier at BMS, Dr. Swaminathan advanced from principal scientist to associate
director, working on approved products including Nulojix&#174;, Orencia&#174; and Eliquis&#174;. Between his tenures at BMS, he spent nearly
four years at Covance (now Labcorp Drug Development), where he rose to Marketing Head, in charge of a $1 billion clinical business. Dr.
Swaminathan received his Ph.D., Pharmaceutical Sciences at the University of Pittsburgh, and is a graduate of the Marketing Management
Program at Wharton, University of Pennsylvania.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Diamond joins Actinium with over 20 years
of experience in patent law, developing and executing IP strategy within the biotechnology industry. He joins Actinium from Enzo Biochem,
Inc., where he was Senior Counsel, Patents and Business Development. As Enzo&#8217;s sole patent attorney and senior-most counsel, he
reported to the CEO and led all IP related and essential in-house legal functions. During his time at Enzo, Dr. Diamond obtained critical,
high-value patent coverage for key products and technologies and managed high-profile litigations and settlement negotiations that resulted
in a number of sizeable settlements. Prior to Enzo, Dr. Diamond first practiced IP law at global law firm White &amp; Case LLP before
opening his own practice, Diamond Law Office, LLC, where he was of counsel to the firms Lucas &amp; Mercanti, LLP and Zuber, Lawler &amp;
Del Duca, LLP. Paul received his law degree from Fordham University School of Law. He also has a strong scientific background, receiving
a B.A. in Biology from The Johns Hopkins University and a Ph.D. in Molecular and Cellular Biology from Harvard University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Desai is a hematologist/oncologist with nearly
25 years of drug development industry experience. Over the course of his career, Dr. Desai has successfully designed and implemented clinical
development, U.S. and global medical affairs, and life cycle management plans for a variety of pharmaceutical products. This has included
participation in multiple INDs, NDAs, and sNDA submissions and efficiently managing the product Scientific Advisory Boards (SAB) and Data
and Safety Monitoring Boards (DSMB) for hematology, oncology, and therapeutic candidates. Most recently, Dr. Desai, served as Vice President,
Head of U.S. Medical Affairs &#8211; Oncology at Glaxo Smith Kline (GSK).&#160;At GSK, he established the U.S. medical affairs oncology
team that oversaw the launch readiness plans for three novel oncology products&#8212;Blenrep&#174; in multiple myeloma, Zejula&#174; in
ovarian cancer, and dostarlimab in endometrial cancer. Prior to GSK, Dr. Desai has overseen the clinical development, implementation,
and delivery of oncology life cycle management plans for various oncology therapies at several leading global pharmaceutical companies,
including Eli Lilly &amp; Company (Lilly), Janssen Pharmaceuticals, Inc. and Takeda, Inc. Prior to GSK, he was the VP of Global Medical
Affairs at Lilly, during which time he oversaw the global medical affairs team for Lilly's GI Oncology portfolio. Earlier in his career,
Dr. Desai contributed to the approval of Janssen's myeloma drug Darzalex&#174; (daratumumab) and leading and strategically executing medical
affairs activities globally for Velcade&#174; (bortezomib). Prior to Janssen, Dr. Desai was responsible for the international development
of oncology products in solid tumors and hematological malignancies at Sanofi, where he successfully executed pivotal trials&#160;that
led to NDA submission&#160;for Jevtana&#174; (cabazitaxel).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with General Instruction B.2 of
Form 8-K, the information in this Item&#160;7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221;
for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the
Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing
of information under Item&#160;7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that
the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required
by Regulation&#160;FD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 7%"><span style="font-size: 10pt"><b>Exhibit Number</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 92%; text-align: center"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td><a href="ea147815ex99-1_actinium.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt; color: #0000EE"><span style="text-decoration: underline">Press release dated September 23, 2021 (furnished herewith pursuant to Item 7.01).</span></span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">1</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 40%"><span style="font-size: 10pt"><b>Actinium Pharmaceuticals, Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Date: September 23, 2021</span></td>
    <td>
    <p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>/s/ Sandesh Seth</i></p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Name: Sandesh Seth</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title: Chairman and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">2</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>



<p style="margin: 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LLMr+rA9OlTEKTJEfC0uSnFrRlqnfpJ/abchhkBI7j25QkzEmlamRobzoizgiE1ba49Q4hUZ7QWDI99sMwizxJtxnrX1w/oDcwoMBmYepzrcB2dnHFYZyHSq1FQlIGeZlHDYiajXc7JXU6H1RtegbQUHppYNes3v8cNRv8hS8x6STsjOkM0gieUof0DJRMGeOv0kvjsoilxEk6EisWZ6tH3Mw3lqYFljE7LciP47+gLeREkZ -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea147815ex99-1_actinium.htm
<DESCRIPTION>PRESS RELEASE DATED SEPTEMBER 23, 2021 (FURNISHED HEREWITH PURSUANT TO ITEM 7.01)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Actinium Announces Multiple Senior Leadership
Appointments Including Chief Business and Commercial Officer, New Chief Medical Officer and Vice President, Patent and Legal Counsel </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: center"><I>Arun Swaminathan, Ph.D. appointed as Chief Business and Commercial Officer, bringing 20+ years of industry
experience in large pharmaceutical and biotech organizations</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: center"><I>Avinash Desai, M.D. promoted to Chief Medical Officer to lead clinical development, clinical operations,
and CMC</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: center"><I>Paul Diamond, Ph.D., Esq., appointed Vice President, Patent and Legal Counsel to execute the Company&rsquo;s
IP strategy amidst its advancing clinical pipeline and R&amp;D activity leveraging its AWE technology platform</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEW YORK, NY &ndash; September 23, 2021 &ndash;
<B>Actinium Pharmaceuticals, Inc.</B> (NYSE AMERICAN: ATNM) (&ldquo;Actinium&rdquo; or the &ldquo;Company&rdquo;), a leader in the development
of targeted radiotherapies for patients with unmet needs, today announced multiple senior leadership appointments including Arun Swaminathan,
Ph.D., as Chief Business and Commercial Officer, Paul Diamond, Ph.D., as Vice President, Patent and Legal Counsel and Avinash Desai, M.D.,
who previously served as Executive Vice President, Clinical Development, Operations and Medical Affairs, to the position of Chief Medical
Officer, effective immediately. These senior leadership additions add over 50 years of experience in key areas aligned with Actinium&rsquo;s
growth strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sandesh Seth, Actinium&rsquo;s Chairman and CEO,
said, &ldquo;I am thrilled to welcome Arun and Paul to the Actinium team. Arun brings a unique blend of experiences across commercial-focused
roles at global biopharmaceutical companies, as well as an entrepreneurial mindset and track record of value creation in smaller organizations.
His scientific training, experience and business acumen make him ideal to lead our commercial planning for Iomab-B, following the recent
completion of the Phase 3 SIERRA trial and to lead our business development activities focused on our clinical assets and AWE technology
platform to further expand our leadership in target radiotherapies.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sandesh Seth, continued, &ldquo;Equally exciting
is Paul&rsquo;s appointment, which coincides with our expansion in R&amp;D, leveraging our AWE technology platform, which is expected
to yield new programs in the coming months. Paul is a highly experienced and proven patent attorney who brings a strong scientific pedigree.
He will be imbedded in the R&amp;D activity at Actinium to ensure our patent portfolio is architected in line with our development objectives
through value-added patent development and prosecution. With our clinical progress led by Iomab-B, novel clinical pipeline of actinium-225
targeted radiotherapies and enhanced R&amp;D capabilities overlaid with our strong balance sheet, we are excited with the caliber of talent
being attracted to and joining Actinium.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;I am excited to announce Dr. Desai&rsquo;s
promotion to Chief Medical Officer, in place of Dr. Berger, who will be leaving the Company effective September 24<SUP>th</SUP>. I have
been impressed with Dr. Desai&rsquo;s execution since he joined Actinium last November. In this short time, he has taken the lead on clinical
operations for Iomab-B and implemented strategies that led to the completion of our Phase 3 SIERRA trial, with the last 25 percent of
patients being enrolled faster than any previous cohort, despite the challenging environment from the ongoing COVID pandemic. Additionally,
he has assumed leadership of our CMC operations and further strengthened its integration with our clinical team. With SIERRA enrollment
complete, Dr. Desai will leverage his extensive drug development experience to execute the BLA filing strategy he has led. Finally, with
his extensive medical affairs experience in oncology, he will be invaluable in our Iomab-B commercial planning. With Dr. Desai and Dr.
Swaminathan onboard, I am confident in our team&rsquo;s capabilities and look forward to working with them in executing our strategic
vision to create value for patients and shareholders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Swaminathan stated, &ldquo;I am excited to
join the Actinium team just as enrollment is completed for the pivotal Phase 3 SIERRA trial of Iomab-B. This is an exciting time in the
Company&rsquo;s evolution, as it sets the stage for us to further leverage the SIERRA study to expand our pipeline of target radiotherapies
across hematologic and solid tumor indications, leveraging our AWE technology platform. With the growing interest in targeted radiotherapy,
Actinium&rsquo;s capabilities, clinical development experience, intellectual property and supply chain set us apart. Through the development
of Iomab-B and Actimab-A, Actinium has gained tremendous insights into the development of targeted radiotherapies across multiple isotopes,
targeting agents and indications, which I look forward to leveraging in my business development efforts. Additionally, through the Phase
3 SIERRA and Phase 1/2 Actimab-A trials, Actinium has developed a supply chain that can bring targeted radiotherapies to the point of
care in many of the leading comprehensive cancer centers across the United States and Canada, where a significant number of patients with
advanced cancers are treated. As we begin our commercial planning, first for Iomab-B, I am struck by the concentrated nature of the bone
marrow transplant market and the opportunity to leverage a conditioning-focused commercial organization across transplant, cell, and gene
therapies for potential future indications beyond acute myeloid leukemia. We believe there is a significant opportunity across several
of these indications, which are expected to build upon the growing awareness of Iomab-B among transplant centers and physicians.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Avinash Desai, added, &ldquo;I am honored
and excited to be promoted to the role of Chief Medical Officer at Actinium. I have a deep passion and energy for oncology drug development
that I will continue to apply to the advancement of Actinium&rsquo;s pipeline of novel and differentiated targeted radiotherapies together
with my amazing clinical development, clinical operations, and CMC colleagues at Actinium. Across our pipeline, I believe we have the
opportunity to transform patient outcomes, particularly in indications not adequately addressed by traditional therapeutics. Iomab-B is
a prime example, as the older, relapsed/refractory AML patients with active disease are not considered eligible for transplant with traditional
cytotoxic conditioning regimens, yet in the SIERRA trial, 100% of patients receiving Iomab-B have accessed transplant and engrafted without
delay. After completing SIERRA enrollment with strong momentum, we look forward to preparing for a BLA filing and with Arun&rsquo;s joining,
beginning commercial planning for Iomab-B. Beyond Iomab-B, our Iomab-ACT initiative for cell and gene therapy conditioning and actinium-225
alpha therapy and combination trials in relapsed/refractory hematology indications have the same paradigm-shifting potential as Iomab-B.
Finally, I am excited to leverage our clinical experience and capabilities with our AWE technology platform to unveil new targeted radiotherapies
to further bolster Actinium&rsquo;s pipeline.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Arun Swaminathan, Ph.D., Chief Business
and Commercial Officer</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Swaminathan is a highly accomplished executive
with over 20 years of experience in the global biopharmaceutical industry, which has included increasing positions of responsibility across
commercial, business development, and clinical roles. He has a proven track record of converting great science into successful business
opportunities. Prior to joining Actinium, Dr. Swaminathan was the Chief Business Officer and Senior Vice President at Alteogen Inc. a
South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics. In this role, his
negotiations with partners led to deals totaling over $6 billion in potential value, including agreements with two of the top ten global
pharmaceutical companies. During his tenure at Alteogen, the Company&rsquo;s market value increased from approximately $400 million to
over $4 billion. Dr. Swaminathan joined Alteogen after they entered into an agreement with Lynkogen Inc. and gained full rights to develop
the assets. As CEO and co-founder of Lynkogen, he raised capital, in-licensed potentially transformative drug candidates to address complex
metabolic diseases and advanced Lynkogen from concept to a pre-clinical stage company with a lead drug candidate ready for IND enabling
studies that he successfully negotiated for out-licensing.&nbsp; Previously, Dr. Swaminathan held commercial and business development
roles at Bristol Myers Squibb over 12 years during two tenures, most recently as Worldwide Brand Director, where he managed products with
over $2 billion in annual sales across the top 10 global markets. Earlier at BMS, Dr. Swaminathan advanced from principal scientist to
associate director, working on approved products including Nulojix&reg;, Orencia&reg; and Eliquis&reg;. Between his tenures at BMS, he
spent nearly four years at Covance (now Labcorp Drug Development), where he rose to Marketing Head, in charge of a $1 billion clinical
business. Dr. Swaminathan received his Ph.D., Pharmaceutical Sciences at the University of Pittsburgh, and is a graduate of the Marketing
Management Program at Wharton, University of Pennsylvania.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Avinash Desai, M.D., Chief Medical Officer</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Desai is a hematologist/oncologist with nearly
25 years of drug development industry experience. Over the course of his career, Dr. Desai has successfully designed and implemented clinical
development, U.S. and global medical affairs, and life cycle management plans for a variety of pharmaceutical products. This has included
participation in multiple INDs, NDAs, and sNDA submissions and efficiently managing the product Scientific Advisory Boards (SAB) and Data
and Safety Monitoring Boards (DSMB) for hematology, oncology, and therapeutic candidates. Most recently, Dr. Desai, served as Vice President,
Head of U.S. Medical Affairs &ndash; Oncology at Glaxo Smith Kline (GSK).&nbsp;At GSK, he established the U.S. medical affairs oncology
team that oversaw the launch readiness plans for three novel oncology products&mdash;Blenrep&reg; in multiple myeloma, Zejula&reg; in
ovarian cancer, and dostarlimab in endometrial cancer. Prior to GSK, Dr. Desai has overseen the clinical development, implementation,
and delivery of oncology life cycle management plans for various oncology therapies at several leading global pharmaceutical companies,
including Eli Lilly &amp; Company (Lilly), Janssen Pharmaceuticals, Inc. and Takeda, Inc. &nbsp;Prior to GSK, he was the VP of Global
Medical Affairs at Lilly, during which time he oversaw the global medical affairs team for Lilly's GI Oncology portfolio.&nbsp; Earlier
in his career, Dr. Desai contributed to the approval of Janssen's myeloma drug Darzalex&reg; (daratumumab) and leading and strategically
executing medical affairs activities globally for Velcade&reg; (bortezomib). &nbsp;Prior to Janssen, Dr. Desai was responsible for the
international development of oncology products in solid tumors and hematological malignancies at Sanofi, where he successfully executed
pivotal trials&nbsp;that led to NDA submission&nbsp;for Jevtana&reg; (cabazitaxel).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Paul Diamond, Ph.D., Esq., Vice President,
Patent and Legal Counsel</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Diamond joins Actinium with over 20 years
of experience in patent law, developing and executing IP strategy within the biotechnology industry. He joins Actinium from Enzo Biochem,
Inc., where he was Senior Counsel, Patents and Business Development. As Enzo&rsquo;s sole patent attorney and senior-most counsel, he
reported to the CEO and led all IP related and essential in-house legal functions. During his time at Enzo, Dr. Diamond obtained critical,
high-value patent coverage for key products and technologies and managed high-profile litigations and settlement negotiations that resulted
in a number of sizeable settlements. Prior to Enzo, Dr. Diamond first practiced IP law at global law firm White &amp; Case LLP before
opening his own practice, Diamond Law Office, LLC, where he was of counsel to the firms Lucas &amp; Mercanti, LLP and Zuber, Lawler &amp;
Del Duca, LLP. Paul received his law degree from Fordham University School of Law. He also has a strong scientific background, receiving
a B.A. in Biology from The Johns Hopkins University and a Ph.D. in Molecular and Cellular Biology from Harvard University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Actinium Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Actinium Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat
patients with high unmet needs not addressed by traditional cancer therapies. Actinium&rsquo;s current clinical pipeline is led by ARCs
or Antibody Radiation-Conjugates that are being applied to targeted conditioning, which is intended to selectively deplete a patient's
disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT)
such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. Actinium&rsquo;s targeted conditioning ARCs seek
to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy
that is used for conditioning in standard practice currently. Our lead product candidate, I-131 apamistamab (Iomab-B) has been studied
in several hundred patients including in the recently completed, 150-patient, pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or
Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. Iomab-ACT, low dose I-131 apamistamab is being studied as a targeted
conditioning agent in a Phase 1 study with a CD19 CAR T-cell Therapy with Memorial Sloan Kettering Cancer Center. In addition, we are
leaders in the field of Actinium-225 alpha therapies. Actimab-A, our clinical stage CD33 targeting ARC alpha therapy has been studied
in nearly 150 patients including our ongoing combination trials with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax.
Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform. This is where our intellectual
property portfolio of over 160 patents, know-how, collective research and expertise in the field are being leveraged to construct and
study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes. Our AWE technology platform is currently being utilized
in a collaborative research partnership with Astellas Pharma, Inc. Website: https://www.actiniumpharma.com/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Forward-Looking Statements
for Actinium Pharmaceuticals, Inc.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This press release may
contain projections or other &quot;forward-looking statements&quot; within the meaning of the &quot;safe-harbor&quot; provisions of the
private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the
Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and
uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks
and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under
development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters,
the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks
detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the &quot;SEC&quot;), including without
limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented
from time to time.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal">Investors:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">Hans Vitzthum<BR>
LifeSci Advisors, LLC<BR>
Hans@LifeSciAdvisors.com&nbsp;<BR>
(617) 430-7578</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>atnm-20210922.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 8qI5s7xRiXgen8uOYHxcWaOGicP9zp5yuZlBvGd8HZk6fygqlKmLPinEqmamIWEG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:ATNM="http://actiniumpharma.com/20210922" elementFormDefault="qualified" targetNamespace="http://actiniumpharma.com/20210922">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://actiniumpharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20210922_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20210922_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>atnm-20210922_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>atnm-20210922_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://actiniumpharma.com/role/Cover" xlink:href="atnm-20210922.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "% @H# 2(  A$! Q$!_\0
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MJD:/+;VTN6+DG9-Z):M6O;5>C^!/^"V'[(>M:EIL6MZQXTT7P/JNM1>'M/\
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MP^%K-XW,)X?"1E&TJRM.5+]$P<C/KZTM-4Y /U]/4^G&?7'>G5X9]:%-#@]
M>N.G?_//&>*9.Q2&5UC>9DC=UBCP))612PC0L0-[D!5R0-Q&2!7YZ_L8_MD^
M/_VFO'7Q=\*>,/@GJ?PRM?AS=HEEJDL^K31B:34KK3SX7\0#5=.T\)XIAA@_
MM&0:<9+4VR7'F00JMK->>[EW#>;YME'$&>X&AAZF6\,4<!B,YJU<?@,-6HTL
MRQBP.$>'PF)Q5'%XZ4L2U&I'!4,1*E'WYI:1?R6><;\.\.\1<'\+9KB<71SG
MCK%YI@>&Z-'*\SQF&Q6)R;+GFN/AB\?@\'7P.5J&"C*=*IF.(PL*\U[.E)N\
MU^A]%%%>$?6A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !16;>ZI9:;")[^[@M820/-GD6) 2>
MF6('(!QWR"..*QQXU\+9R?$&E@9/'VN'(QVY8<_Y]*+2:ORRMW49-?>HM/U3
M:\R>:.JYHW6ZYHIJUFW9S3MKO:QU5,=@BLQ.  23TP!R3GM@#K7,'QMX4!./
M$&EGMM^UPC''KN]OUKF_%GQ%\*Z;H>H7 \1:8KBWEV%;R'Y24;:00X/MC@GD
M5K1HSQ%:G0A&7-5J0IJZ:5YR4;7LN_EZK<SK5H4:-2M*4>6G3E-NZ:M&+?23
M=FTM;6=]&?S:?M]_\%I]8T#]JSQ[^RO\&-3\+>#/#OP=N)O#OQ#^)'B30U\4
MZCXC^($&G1ZAJ?AGP[I%W?6&F:3H7APW$6F7^K7"WNI:IK27T5FMA9VD4M]T
M_P#P3M_:^C_;IM?'.D7VGV5A\2?A=K&EV7B.'1UN$T#7M#\01W4GA_QEI-M=
M3W-S8R7LNGZE8ZKI4ES=1Z;?V@:UN)+:]@6/^?+_ (*)?L5_$"Z_;,^+/Q0^
M'LMAXF\+?&/QIJ'CNZ(U6UM[WP]XCU=H1K<%S%/(IO-+O;Y7U&QNK7S7@%W+
M97$,?D12S?T!_P#! S]CV;]FO0?BE\3_ (DZWHZ^*?B=+H%G;Z?!<H]MI/AW
MPTM]-96SW,CK]IO;[4-4O+RZ:)?)ACBLH5>1TD8?U=BL5PUP3X>T*F I8*CG
M,*.&H\L)\^98_&U(16*JXE\\I*C!RG43E"G3I0C2A#2\I_AE;+)<9YTE4J5:
MU*515%5B_P!SAJ5.=O9\DK)Z))I7;;NV^O[P>&?V>O"5YH\<'BK2;;4_,569
M+B-'*D@9(+ E2>YZ]OK['X.^&_@WP' \'A?1+32UD)\QX(U$C9XP7QNQCC!)
M_08T%\9>% H U[3.@  NH>G0#[W.!@>^*>/&/A?G_B>Z:>XQ<Q=/P;GZU_+F
M:9MC,WQ53%XVK.K4J-M7;:C!WM".]HI6TNM+=C]GRW+,%E6&IX;"4H4H0C;F
MY8QE-V2<I223DW9ZWVT6ATQ /7M17,?\)?X:P2-=T[C_ *;Q#G\Z</%_ALX(
MUK3P#V^T1DG'X^X__77G;=&M4MM/*V^GFM.YZ5UZ^EG^ITM9>L:/I^NZ==:5
MJENEU97<;QS0R*&4JP*]P<$ \'KZ5G_\)=X:S_R&K#&.GGI]<YSTQ^%*?%GA
MXD;=8L?^_P G/]>V..N1BG:2=TIWT2Y5)N[VM:VOHUZBT>ZT[NUO1N]O5-];
M-:GP7KW_  3<_9[/BC4?'>C>#]'LO$5[=-J$]U:Z/IMO=7-WDD37%U!;1SW$
MQ).9I7:4C@OQSY5XJ\%7W@F^^S0P&%+;$:(B^6DL,9VJO' E4<1.,=-C$KR/
MU<L-3T_58VEL+NWO(@V"\$JR*#CH2I/(YSZ>M>3_ !7\!6FO:->WT$,?VZUM
MY9X69?D\R-"R;P.2FX OZKN'4U^E\$\<XG*,5#"9E6J8C 5E&DIUZDZKH1>D
M%&52=1QI)R6B?+%6:BK'YQQMP72SG"RQ6!@J6-HJ4XQI*,?:7:;:Y;)25G+1
M:I26[5OS*TO_ (*,_ #X*^*-4^'GCCXC,?$&@VT$WB>QT'P_XE\6CP-#=QK+
M;2>,Y_#VFZA!H#^1+'<RV5P[:E!:E+J>RC@>.1_YM_\ @NM^RO\ '+]ISQ1H
MW[8WPF\=:O\ &'PC!X-M9=%\":+K)\1>%-8\#Q>;=Q^*/@^;-FMTU:6-I)_$
MGAI#)=:Y<0/-9&'5[>;3)?QPUOXG_''X=?%KXZ^%?%UYJ>G^.KGXC?$+3OB%
M%J?G#4YM<G\5:C<WMQ*)=LF+TM%=64Q^2;3Y[9X,P-'G^JC_ ((66%_X\_8X
M\2_#CXNQW<WAN[^+OB_6OAH^HJ5ETG0]5M-%?4QI9D42V^F7'BV+7-0MD5_*
M:>>ZFMPL<WS?LO%'#,>'Z& X_P"$YRGFL7!8[!UX4*N!S3 XJDI8FG1A3INK
M3O2Y5*I2FZL;QK0J0G"4*OS628V,<-_JWGV)E/!U'&E1Q4?:4J^&QB_A-7:O
M3YTUR2O&224G8_#+_@DI\)_%GQYM/"OA#X1^'K76/B3XFUGQ#/>2WT,\>A^"
M]#T35ETK4O''C^=!]JL](T8[+*RTTE-3US5DCT#2HQ<R7,]I_?S^R_\ LS^"
M/V8/AW;>&-!,NK^(+WR=2\;>-]3BC&N^,O$9@2*ZUC5'CRL$2*/LVD:1;L-/
MT'3$@TVPC6.)Y):?[,W[)7P*_9GL_&&H?"?P+X7\,ZU\2]>7Q9X_\0:)I5K8
M:CXM\0+;):KJ>LW$*!IYE@CR8T\NV:YFO+XP?;K^^N;B?]I+XGZCX4^'_C"#
MPA<K#XL/AC7T\/RY&(->;2KM='G<Y.%AU%K63D8&PDYP!7X[Q)Q'F'B%FV$R
MW+<#5RW TO97P;FZM2>*Y(_6<3BZT(052G2JRJQPE%Q4:5*"J2YJU2?)]S@L
M'@^$\NKX[&8N&*JOGY:[M"'LY2E[&E2BY-IRAR2JR3<G.4HI^SC%/Y+_ &CO
M^"E7[,W@3Q;XF^%LGQ.AG\0^#[H:9X[N?#VBZ_XDT'P)J##+:?XP\1:%IM]I
M.CW]NN/M]F;FXNM*8[-6BL70J.,\/RK\1&TS5]'O+77=%URVM=3T?4]/N8K_
M $_6+"_B2>TU.TNX&D@N;&Y@>.6REB=XYE82@E>*_P ^3PC\7/BWX6@\8>$=
M7OM2L];U'5-3M?'-KJ9F.L-XF359Y=?&HF4^>=1GU9[V6^DFS)/-(\FYA(&;
M^['_ ((!_#[QDW[!/P[UKXCP7XDD\5^/[WP/#J\4J7,'P]O/$D]SX<2".=?,
MCTV69M3N](C8!%TRXM?(46OD ?M&999D?AEP?A<PP4ZM>MB%3H5)XET(U,5C
M*E!U'.A"D^=4J<E*,X-U.2')*<HN6OYGC<MS'C3.Z4:V(:A";J3H04ITJ6&<
ME9J7\-M0<;.Z>NB=F?I;\.?V5?AQ;SP>)==\,6-SJ[%9O->%>9 =VYT(*L0W
M7/(Q^-?8-K:6]C;PVMI#';VT"".*&) B(B@!0JJ   !CBID144*@"JH  '
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M:_\ !;FTB/PI^"%YY2&:'Q]XHM4F.T2I'>>#KB:6!&VEA%,]C#)(H.TO!$S
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MJW_!H?=ZE',D7[7K6CR(5$G_  K4/L8_<8*?$J[PK ':VW(R,@X8?H&7^)G
M5&$XULSPR<H2CKE%5\SE&4+<W]F-+XN]N[6Y\OB>$^(JE13IX6M)J<7=XRDD
ME&46O^8I;6;6G2RN[']*'_!,G6]5UOX%:+<:K?W6H3+HV@J);N5YY3_Q)K#E
MI9&9W8_Q,S%B<LQ)))_262-)8WBD4.DBLCJ>C*PP0>O!%?,/[*_[/Q_9Y^']
MCX+.I_VJ;*RT^R-WL\H3&QLK>T,OD[W\KS3!YH3>Y0-LW-MW'ZAK^29M2J3D
MG=.<Y1>NJ<I-/6S5U*]FDUM9'[1%>ZDTK<J5NB225O1;=M--+'Y"?M4_\$IO
M@)\:?',_Q<D\'>'!XR>-%O-6DT:T?4[J"#B*&YNHTC>]2%69(/MHG\A,)$40
M*HX/P;\.;#X(65KX<T*T6PL=-\J'RX8E@2W,("(\4:*B);X"JT:*%CR'4 %S
M7[:21K*C(X!5A@@C(KX[^/O@/2[*SN_$?RPPVT$]W>!%!<P01/+.54'YF,:-
MA#@$D+ZFOV#P[XRJ4ZM+(LUJ5,1AIJ5+!NK4JU514E;V,(3G.$(RT7N0BGU/
MRCQ#X6EB<-+-LO;I5</:K5IPY8QFT[^T5DFVOM)WTU5M$9W@SXW?8_#DUI>,
M[7$4&%< MCY<!F8 \< @DX-?-'C7Q%>^,=3N8I&:5;K<LF3G9!(=I &,;Y!E
M4! XW28 45_'/K/_  5)\?\ Q0\;?$KQ9K?C/QWX9M&U+58OA)X5\'>*M:\.
M:/X'TK3]1FM=&6.VT>ZM(=3U>;3XTN]:U77$U"6]OY)8E6*Q6"TA_I-_X(^_
M'/Q!^V?\#+7QA\01')XX\&^-M<\ ^*-76&WM8_%DFC1:;J.E>)FM+>."VMKV
M^T;5K*#5K>UBCM?[3M+J>WCCCN/*C_8:_"^3\'X7&<41C1DL5!U*L:2G+ZO.
M</:0IN\%%N?O1DH64)IQE>+4E^>8V7$F=4<KR?$UHRITYTZ,J<9VDG)6CSRO
M>:5K<ZM:]]#U?PU_P27^!7Q/^(+_ !5\2>"O#C:E?30W%_<W&B6CW6H&';M-
M]*$5+UP@V"6\BGE*!4+LJA1^VG@;P5H7P^\-:9X5\/6D5GIFE6L%K;0PQK%&
MD4$:Q1HD<:I&D:(BHB(JJJ (   *V-&TNWTFR@M+>-42.)5^48!P!U/?//!^
MN*UZ_F#B;B/&<18Z5:O6JO"T9U%@\-*K4G1H4W)W]E3G4E"FY67-[.$$]K=#
M]^X?R2CDN7T</%*=94H*O6DE[2I**V<E]E=%>W6R=PJ%V<-@'@X/N,8R,X(
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MV+W,D@^D,#C@<<C@<>XH(!Z@'ZC->9F/'W%^:9AE^:XG.'1QV5YE#.<#5RW
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M#8:E"C0ISQ6.Q&*QF(=.E3ITU5Q.)Q%>4*=-5*U1PBT4445@=H4444 %%%%
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MD.K_ +7/CVR+&#]HKQ<5 X5O#?@,]#STT'OR#ZBO*=:_;G^+%GO%M^T7XF0
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M  41\ ?M2^)=0^'5YX2U?X8?%"PL;G4(O#&LW\.IV.N6^FLL6L+HVIQVNG7
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MX O_  G:^'[:76)=6UZ^@UVWUJ2\GUV1;6UL+:>.;2T6&UL8Y%A626.6YN'
M>OOY2 H!;G'<^P]>W3G^72OPC_X(K\2_M/\ 09U_P*!_W\\;  >O/05^@US^
MUGXD\9>,_B%X/_9Z^!FM_&Z'X4:S)X7\=^+9/'7A3X=^%H/%MO$9KSPOX:O-
M?6_O/$NJ:>H2/4)(K"QTJ"=EC&H2!D9_N/%;@"CEGB9Q=D/!^5PP60Y#ALAK
MS^LYC2HX'+*.8Y1DSC/'9MG.,HTHSQF9XRI3I.OB55Q.)J2IT:$E":P_Y5X
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M?QS%X5GO(C_PCNE:;H-IH^E1W\[.((;R6TLKC5-8<,;>S2>&":?-K+Y?[@>
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M+28[AED3U']D[]B+P]^R[IGBK3Y/B%XG^*0\16/_  CUG;^++>&WT/P[X/\
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MXH<:Y)]*_))952X/Q'C%QCPSQCP7C\=Q#D>98'$TN%<OX;P<>'^(J.1SKXS
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M<YQE=8/&XZK4I9;BJ>)EAL/AL#%U9XC$*+A2E.5.A"2YJU1124OW#QLR;/\
MB7PG\0.%N%\HEG6>\5<*9YPSE^%_M++,IHTJ^=Y=B,!#&XO&YK..'IX/!RJJ
MKB(TXU<54A:&&HU)N7+\\?\ !'OC]DF]! S_ ,+<\:CKT_T'P[SGH#]3].17
MS1^V#:6UM_P5;_97N!!#(VH#X//>!X(L3-'XU\46<4LS%2TKQ*EOAW+NJQQQ
MJRHB[?T(_9G_ &*[S]EZYM=/\&_'_P")6L_#U+[5=5U#X9ZYHW@8^'=4U75;
M+[+)J#W]KX>B\0V-Q'/':7O_ !+]5MXI9K.*.:-X&DC?S/XA?\$X9/B9\6M.
M^-WB;]I[XQ2_$70+RPN?">N6VB_#FT_X16'1M3N=5T*QTFSMO"\-C]FTFZNI
M7C^U6UQ-=NTDE_+<O+)N_9\#QSP11\8_$?C2IQ/.GD'%>1<<X3+JD<AS^6*>
M*XPR>IE>$H8K"0A"K167UU'%XVJJM2BZ4J:P?MZ\9QA_,6:>%/BGB_HU>#GA
MA2X$A4XNX XJ\+L=FU&KQ9P@LO>!\/>(Z/$&8X[ YA*K4HU_[6P\ZV79;AI4
M:.*AB(3EF'L,'*$ZE3_@KC;02_L<ZY+*BM+9?$3X=W4#XP4E;6I+7<2.N8+F
MXC.2#MD8$X)!\!^)>I^*]-_X(U>#I/#9ND-Y\/?A[I?B*6!I%EB\(:AXOMK3
M6EWH=Z6<]H\-C=]$.FW,R.?)9A7W1^T=^Q_J/[2_A7P_X&\7_'GXAZ1X/TO2
M]"BUW0]$T+P$L7C#Q-H,KSP^,=9NKGPY)>VVHW$[K--I>E3V6@I+%&\.FQL,
MUW'P7_9GL/A7\)+_ ."'B?QQKOQB^'<^EMX=TW0O'FC>%XX-(\)S6<EG=^&(
M_P"P=)TV34M-N!-)(KZO)>WMJ2D=K<Q111(G@9#QUPQP]X>\!Y;/&0SG..%/
M%S_7W%Y&\NS*E0Q.3_5LOP3P5+'XJDL"\9.672QSC47LJ?ML(E.I6AB:</L>
M*_"KCSC'QD\4L[AEE;AKACCWZ.\_"/ \4PSS):V-R_B&6,S+-%F-;*<!B5FO
M]GTXYM_9<*M*J\2ZF'S"484<'7P=>KX!_P $M/$WA?7/V./AYI?A^:S;4O"6
MI>+M$\664#)]KL=?E\3:GJV^^B3$BR:AINH:=?6\T@(G@E7RRRQL%^M? OPU
M^"?PZ\:>.)_ 'A;P3X4\?>.C:^+/',&A)86GB'6XI;N\BM-<U'38Y?M4&G7&
MI-J)CGCM;>PN-4:^E DO9)W/P9I?_!+R+X9>,M3\4?LW?M-?%WX$V&MCRM4\
M/Z9#I_B6WDLPQ>*R2ZO;K3_MEO9,\O\ 9KZ_:ZW>V8D)6]9VE>7[0^!O[-GA
M+X(GQ-K:Z_XL^(WQ)\=M:-X\^*OQ#U0:SXT\31:>CQZ;I7VJ**VM='\/:4LL
MW]EZ%I-O;6=JTKRL)I]LJ_/^(>+X/Q^<\7\1\+\<YQB\-QCCJF:?ZMSR7.,N
MQ\:^/S"&:8C!<28JMCH9'B\%E>*JXNIA*N$_M*MB*T<#+#X?".G6Q4?J_!O*
M_$K)N&?#G@GCKPLX<P.-\.,NHY(^-J?$O#>;Y55P>5Y17R;#9MP9@<)E<N)<
M!F^>8..!P^/HXVGDF%P>'GFCQ&,QOM\/@Y==X&^/7P:^)GBGQ3X)\ ?$CPGX
MM\6>"IY(/%&@Z)JL%Y?Z2\-P;.X>2)2!=6]M>#['=75BUU:VUX1:SS1SLL9]
M<K\\OV8/^"=OP_\ V8/C!XP^+?A_QOXF\37&N6&LZ-X:T+5K2QM+?POHVO:I
M:ZKJ%M<WUH[3^(;L26-K:VE[<0V AM4D:>VNKR7[4GZ&U\1Q?A.$\#G"H<%Y
MQFF>9)_9^657CLWRVGE>+695L'3GFF%6&ISG%T,+C'.E0K73J0NKU%3C7K?J
M_ASF7B%FG#M3%>)O#>1<*\2K.L\P]/*^'LYJ9[E\LCP^8U:618^6-J0A*.+Q
M^7*%?%8>S5&IROEHNK+#T"BBBOF#[P**** &LJNI5@&4C!!&1^M>/^//A1I/
MBF&22.&.*YQG>H 8GGDX ],D\8([BO8J,9_G7=@,QQF5XB&*P5:=&K!IIQDT
MI6:=I*]FM.J9Q8_+\)F5">&QE&%:E---2BFU=-7BVKIZ][>1_G\_\%^]#^,'
MP>_;0^%'B-Q?6O@2Y^$MOHW@/50LXTJW\3Z;XFU;4/%NG>8%%O'J]W%=:!J#
M1%_M%[80P%5:*R?R_*_^"2_C/XQZ[^W1HGQ%MKO69]/MO 7C33O'5_ LD=C=
M:5K=K:II&F73L5BDD?Q%;Z??V-N"9E;3;BX3:B2FO[N/VE_V2OA'^U+X97PS
M\3_"^B>(;*.9+F&+6=*L]4MX[J(,(;E(KJ*3R;F$.XBNH#'<1AW"2*'8'QGX
M0_\ !.[X,?!>T>+PEI%AI\C#:@L;*"SBC &U#B-07902 SLS*"54[217[YDO
MC1@GD#R;.\OQ%3%5+TJN*]I1J8*5%SBW-X?E]K[5Q3C*#7(W&+YVG8_-,UX!
MQ-*E.&3U:4:2IRA0I2C)5:;E=ZROR22;;C)6E=OF3W.*T7XU>(]*VH]]+@$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>ea147815-8k_actinium_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atnm-20210922.xsd" xlink:type="simple"/>
    <context id="From2021-09-22to2021-09-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2021-09-22</startDate>
            <endDate>2021-09-22</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-09-22to2021-09-22">0001388320</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-09-22to2021-09-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-09-22to2021-09-22">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-09-22to2021-09-22">2021-09-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-09-22to2021-09-22">ACTINIUM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-09-22to2021-09-22">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-09-22to2021-09-22">001-36374</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-09-22to2021-09-22">74-2963609</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-09-22to2021-09-22">275 Madison Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-09-22to2021-09-22">7th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-09-22to2021-09-22">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-09-22to2021-09-22">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-09-22to2021-09-22">10016</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-09-22to2021-09-22">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-09-22to2021-09-22">677-3870</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-09-22to2021-09-22">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-09-22to2021-09-22">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-09-22to2021-09-22">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-09-22to2021-09-22">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-09-22to2021-09-22">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-09-22to2021-09-22">ATNM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-09-22to2021-09-22">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-09-22to2021-09-22">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139688962672984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 22, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 22,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACTINIUM PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001388320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">74-2963609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">275
Madison Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">7th
Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">677-3870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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MU\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK
M>MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ
M!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.
M\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    (  U(-U,'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ #4@W4_#GRV_M    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ #4@W4YE<G",0!@  G"<  !,
M     ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  -2#=3
M<K'Q65H$  #>$   &               @($,"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ #4@W4Y^@&_"Q @  X@P   T
M     ( !G P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  -2#=3EXJ[',
M   3 @  "P              @ %X#P  7W)E;',O+G)E;'-02P$"% ,4
M"  -2#=3JL0B%C,!   B @  #P              @ %A$   >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ #4@W4R0>FZ*M    ^ $  !H
M ( !P1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M#4@W4V60>9(9 0  SP,  !,              ( !IA(  %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&      D "0 ^ @  \!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea147815-8k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ea147815-8k_actinium.htm">ea147815-8k_actinium.htm</File>
    <File>atnm-20210922.xsd</File>
    <File>atnm-20210922_lab.xml</File>
    <File>atnm-20210922_pre.xml</File>
    <File>ea147815ex99-1_actinium.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea147815-8k_actinium.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ea147815-8k_actinium.htm"
     ]
    },
    "labelLink": {
     "local": [
      "atnm-20210922_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnm-20210922_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "atnm-20210922.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ATNM",
   "nsuri": "http://actiniumpharma.com/20210922",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea147815-8k_actinium.htm",
      "contextRef": "From2021-09-22to2021-09-22",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://actiniumpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea147815-8k_actinium.htm",
      "contextRef": "From2021-09-22to2021-09-22",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://actiniumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001213900-21-049470-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-049470-xbrl.zip
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M/NMC*RACE*33)PJ%;?FD01@WK1'B>V@)98R2:X;$H7 >6#V*\)%(Z.HC78=
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M7UD:2D4BN%=E-M5F^;BRL]4Z*;ZFRLQ0]_LK3EGDUE>LARF.*?OZBO/S#:9
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M3B22>TM3!N(G03H./?!B$\*VO.3IO1" 5<!J0*,.IW4N\&NI!A):/%_H+1#
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M")4P&"*NN>.@QO[,HFP)>C_<X:.%M,E="!M2('K"]6@68+9#]C%ORD@1E39
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MTO<>WKJCXDTZL,G*056'>T_VJ!,?86<E*8/TR+54/68'PF?5;'W,^F^?HEG
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M4$L! A0#%     @ #4@W4QX*+I\9'0  ?(   !@              ( !(A8
M &5A,30W.#$U+3AK7V%C=&EN:75M+FAT;5!+ 0(4 Q0    (  U(-U-3_72]
MQQP  )EC   ;              "  7$S  !E83$T-S@Q-65X.3DM,5]A8W1I
>;FEU;2YH=&U02P4&      4 !0!4 0  <5

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
